LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.55 -0.33

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.11

Max

27.89

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	10.542 61.417
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+48.43% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	105M 1.7B
Ankstesnė atidarymo kaina	27.88
Ankstesnė uždarymo kaina	27.55

Naujienos nuotaikos

By Acuity

67%

33%

313 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-13 19:08; UTC

Svarbiausios naujienos

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

2026-03-13 18:48; UTC

Uždarbis

Pagrindinės rinkos jėgos

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

2026-03-13 17:10; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026-03-13 17:10; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026-03-13 16:47; UTC

Svarbiausios naujienos

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

2026-03-13 22:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026-03-13 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026-03-13 22:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026-03-13 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026-03-13 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 20:02; UTC

Rinkos pokalbiai

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026-03-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026-03-13 19:35; UTC

Svarbiausios naujienos

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

2026-03-13 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2026-03-13 18:49; UTC

Svarbiausios naujienos

The Iran War Could Upend AI. Here's How. -- Barrons.com

2026-03-13 18:24; UTC

Svarbiausios naujienos

Impact of Middle East Conflict on TotalEnergies Activities

2026-03-13 18:00; UTC

Svarbiausios naujienos

Is War Good For the Economy? -- WSJ

2026-03-13 17:23; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

2026-03-13 16:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

2026-03-13 16:38; UTC

Svarbiausios naujienos

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

2026-03-13 16:34; UTC

Įsigijimai, susijungimai, perėmimai

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

2026-03-13 16:33; UTC

Įsigijimai, susijungimai, perėmimai

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

2026-03-13 16:32; UTC

Įsigijimai, susijungimai, perėmimai

EQT Completes Exit From Galderma

2026-03-13 16:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-13 16:15; UTC

Svarbiausios naujienos

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

2026-03-13 16:11; UTC

Rinkos pokalbiai

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

2026-03-13 16:00; UTC

Svarbiausios naujienos

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

2026-03-13 15:48; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

48.43% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 48.43%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

313 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.